Trillium Therapeutics Inc. (TRIL) 20.67 $TRIL
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Apr 20, 11:47AM CDT
SPPR: 2.55 (-0.16), FNRG: 3.11 (-0.86), BIOC: 3.15 (+0.02), NVGN: 7.40 (-0.30), AMPE: 2.89 (+0.20), TRIL: 20.67 (-2.53), CZR: 9.68 (-0.24), TLOG: 4.70 (-0.21), BCLI: 4.29 (-0.09), STDY: 10.10 (+0.11), GENE: 4.88 (-0.05), FARO: 44.64 (-0.93), ICON: 27.06 (+0.45), XXII: 1.50 (+0.04), XBIT: 27.55 (+0.18), UEC: 2.12 (+0.29), COOL: 1.40 (-0.21), CALA: 12.93 (-1.06), WPCS: 3.71 (-0.17), VIMC: 13.42 (+1.31)
Trillium to Provide Update on CD47 Program at the 2015 American Association for Cancer Research Annual Meeting
GlobeNewswire - Thu Apr 16, 7:45AM CDT
Trillium Therapeutics Inc. (Nasdaq:TRIL) (TSX:TR) an immuno-oncology company developing innovative therapies for the treatment of cancer, today announced it will be providing an update on its SIRPaFc immune checkpoint inhibitor program, targeting the CD47 protein, at the 106 Annual Meeting of the American Association for Cancer Research. The meeting will be held April 18-22, 2015 in Philadelphia, PA. Details of the poster presentation, entitled "Lack of CD47 membrane mobility contributes to the poor erythrocyte binding of SIRPαFc, a novel CD47-blocking cancer immunotherapeutic", are listed below:
TR.TO: 25.35 (-3.13), TRIL: 20.67 (-2.53)
Trillium Therapeutics Is An Overvalued Biotech Stock
Pitbull Trading - Seeking Alpha - Tue Apr 14, 8:35AM CDT
The purpose of this article is to thoughtfully explore the fundamental reasons why Trillium Therapeutics (NASDAQ: TRIL ) is extremely overvalued in today's stock market, and to explain the significant risk-factors that contribute to this investment...
IBB: 363.84 (-0.66), TRIL: 20.67 (-2.53), CELG: 115.54 (+0.72)
Trillium completes equity offering
Seeking Alpha - at Seeking Alpha - Tue Apr 07, 3:20PM CDT
TRIL: 20.67 (-2.53)
Trillium Therapeutics Announces Completion of Public Offering of Securities
GlobeNewswire - Tue Apr 07, 3:01PM CDT
Trillium Therapeutics Inc. (Nasdaq:TRIL) (TSX:TR) an immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has completed its previously announced underwritten public offering of common shares and non-voting convertible preferred shares. In the offering, Trillium sold 1,750,754 common shares and 1,077,605 Series II Non-Voting Convertible First Preferred Shares at a price of US$19.50 per share, including 228,359 common shares sold pursuant to the full exercise of the underwriters' option to purchase additional common shares. The gross proceeds to Trillium from this offering, before deducting underwriting discounts and commissions and other offering expenses payable by Trillium, were approximately US$55.2 million.
TR.TO: 25.35 (-3.13), TRIL: 20.67 (-2.53)
The Top-Performing Biotech Stock During a Sizzling First Quarter
at The Street - Wed Apr 01, 8:30AM CDT
That was one crazy first quarter for the biotech sector. Here's where biotech stocks stand on April Fool's Day.
CRMD: 8.86 (-0.28), BIIB: 423.57 (+1.46), ESPR: 100.53 (-2.60), FMI: 48.71 (-0.96), ANTH: 4.79 (+0.10), XBI: 232.63 (-0.32), IBB: 363.84 (-0.66), TRIL: 20.67 (-2.53)
Trillium prices equity offering
Seeking Alpha - at Seeking Alpha - Wed Apr 01, 8:06AM CDT
TRIL: 20.67 (-2.53)
Trillium Therapeutics Announces Pricing of Public Offering of Securities
GlobeNewswire - Wed Apr 01, 6:00AM CDT
Trillium Therapeutics Inc. (Nasdaq:TRIL) (TSX:TR) an immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has priced an underwritten public offering of 1,522,395 common shares and 1,077,605 non-voting convertible preferred shares at a price of US$19.50 per share for aggregate gross proceeds of US$50.7 million before deducting underwriting discounts and commissions and other offering expenses.
TR.TO: 25.35 (-3.13), TRIL: 20.67 (-2.53)
Trillium Therapeutics initiates equity offering
Seeking Alpha - at Seeking Alpha - Mon Mar 30, 3:16PM CDT
TRIL: 20.67 (-2.53)
Trillium Therapeutics Announces Proposed Public Offering of Securities
GlobeNewswire - Mon Mar 30, 3:01PM CDT
Trillium Therapeutics Inc. (Nasdaq:TRIL) (TSX:TR) an immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it is offering to sell US$50,000,000 of common shares and preferred shares in an underwritten public offering. The preferred shares are being offered to certain of Trillium's existing shareholders whose purchase of common shares in this offering may result in such shareholder, together with its affiliates and certain related parties, beneficially owning more than 4.99% of Trillium's outstanding common shares following the consummation of this offering. Trillium also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the total number of common shares to be sold in this offering.
TR.TO: 25.35 (-3.13), TRIL: 20.67 (-2.53)
Trillium Announces Appointment of Eric L. Sievers, M.D. as Chief Medical Officer
GlobeNewswire - Fri Mar 27, 6:00AM CDT
Trillium Therapeutics Inc. ("Trillium"
(Nasdaq:TRIL) (TSX:TR), an immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that Eric L. Sievers, M.D., has assumed the position of Chief Medical Officer. In this role, he will lead the company in evaluating and implementing clinical development strategies for advancement and approval of its clinical programs, with initial emphasis on the company's CD47 program.
TR.TO: 25.35 (-3.13), TRIL: 20.67 (-2.53)
Trillium Therapeutics to Present at the 5th Annual Cancer Immunotherapy Conference
GlobeNewswire - Wed Mar 25, 1:45PM CDT
Trillium Therapeutics Inc. (Nasdaq:TRIL) (TSX:TR), an immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that Robert Uger, PhD, the Company's Chief Scientific Officer, will be presenting at the 5th Annual "Cancer Immunotherapy: A Long Awaited Reality" Conference at the New York Academy of Medicine in New York City on March 26, 2015. The corporate presentation is scheduled for 10:00 AM Eastern Time and Dr. Uger will be participating on the panel: Checkpoint Modulators - Next Generation.
TR.TO: 25.35 (-3.13), TRIL: 20.67 (-2.53)
Bloom Burton's David Martin Zeroes In On Under-The-Radar Biotech
Life Sciences Report - Seeking Alpha - Fri Feb 13, 9:24AM CST
Biotechnology indices have been on a rapid ascent for three years, and 2015 appears to be off to the races as well. Bloom Burton & Co.'s David Martin has taken his seat in the grandstands, betting on specialty pharma and biotech companies based...
AUPH: 3.85 (+0.05), TRIL: 20.67 (-2.53)
So Far in 2015, This Choppy Market Is for Stock-Picker's Only
at The Street - Wed Jan 28, 12:55PM CST
With no clear direction in the market, picking individual stocks has been key to making money in 2015.
HABT: 33.00 (+0.55), EPRS: 8.74 (-0.25), TRIL: 20.67 (-2.53), FSI: 1.46 (+0.03)
Trillium Therapeutics Starts the New Year on a Surge of 28.5%: Analyst Report Issued by BrokerBank Securities, Inc.
PR Newswire - Fri Jan 09, 6:00AM CST
Trillium Therapeutics Inc. (NASDAQ: TRIL) based in Toronto, Canada has seen a price surge since its recent listing on the US NASDAQ exchange. The immune-oncology company is focusing efforts on the flagship SIRPaFc compound and is expected to submit an IND in mid-2015. Moving to the US market and consolidating the shares proved to be very profitable for the company and helped appreciate the share price nearly 100% on both the TSX and NSADAQ tickers.
TRIL: 20.67 (-2.53)
After CAR-T: Getting Ahead of the Next Hot Trend in Cancer Stocks
at The Street - Tue Jan 06, 7:30AM CST
Here's how investors can help fund the next cure for cancer: anti-CD47 antibody therapies.
BLUE: 136.49 (+1.22), KITE: 57.56 (-1.43), JUNO: 55.72 (-0.68), TRIL: 20.67 (-2.53), CELG: 115.54 (+0.72)
Trillium Therapeutics up premarket
Seeking Alpha - at Seeking Alpha - Wed Dec 31, 8:26AM CST
TRIL: 20.67 (-2.53)
OTC Markets Group Congratulates Trillium Therapeutics on NASDAQ Listing
PR Newswire - Mon Dec 22, 7:00AM CST
OTC Markets Group Inc. (OTCQX: OTCM) congratulates Trillium Therapeutics Inc., an immuno-oncology company developing innovative therapies for the treatment of cancer, on its recent NASDAQ listing. Trillium previously traded on OTCQX®, the best marketplace for established, global and growth companies operated by OTC Markets Group.
TRIL: 20.67 (-2.53)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Apr 20, 11:47AM CDT
SPPR: 2.55 (-0.16), FNRG: 3.11 (-0.86), BIOC: 3.15 (+0.02), NVGN: 7.40 (-0.30), AMPE: 2.89 (+0.20), TRIL: 20.67 (-2.53), CZR: 9.68 (-0.24), TLOG: 4.70 (-0.21), BCLI: 4.29 (-0.09), STDY: 10.10 (+0.11), GENE: 4.88 (-0.05), FARO: 44.64 (-0.93), ICON: 27.06 (+0.45), XXII: 1.50 (+0.04), XBIT: 27.55 (+0.18), UEC: 2.12 (+0.29), COOL: 1.40 (-0.21), CALA: 12.93 (-1.06), WPCS: 3.71 (-0.17), VIMC: 13.42 (+1.31)
Trillium to Provide Update on CD47 Program at the 2015 American Association for Cancer Research Annual Meeting
GlobeNewswire - Thu Apr 16, 7:45AM CDT
Trillium Therapeutics Inc. (Nasdaq:TRIL) (TSX:TR) an immuno-oncology company developing innovative therapies for the treatment of cancer, today announced it will be providing an update on its SIRPaFc immune checkpoint inhibitor program, targeting the CD47 protein, at the 106 Annual Meeting of the American Association for Cancer Research. The meeting will be held April 18-22, 2015 in Philadelphia, PA. Details of the poster presentation, entitled "Lack of CD47 membrane mobility contributes to the poor erythrocyte binding of SIRPαFc, a novel CD47-blocking cancer immunotherapeutic", are listed below:
TR.TO: 25.35 (-3.13), TRIL: 20.67 (-2.53)
Trillium Therapeutics Is An Overvalued Biotech Stock
Pitbull Trading - Seeking Alpha - Tue Apr 14, 8:35AM CDT
The purpose of this article is to thoughtfully explore the fundamental reasons why Trillium Therapeutics (NASDAQ: TRIL ) is extremely overvalued in today's stock market, and to explain the significant risk-factors that contribute to this investment...
IBB: 363.84 (-0.66), TRIL: 20.67 (-2.53), CELG: 115.54 (+0.72)
Trillium completes equity offering
Seeking Alpha - at Seeking Alpha - Tue Apr 07, 3:20PM CDT
TRIL: 20.67 (-2.53)
Trillium Therapeutics Announces Completion of Public Offering of Securities
GlobeNewswire - Tue Apr 07, 3:01PM CDT
Trillium Therapeutics Inc. (Nasdaq:TRIL) (TSX:TR) an immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has completed its previously announced underwritten public offering of common shares and non-voting convertible preferred shares. In the offering, Trillium sold 1,750,754 common shares and 1,077,605 Series II Non-Voting Convertible First Preferred Shares at a price of US$19.50 per share, including 228,359 common shares sold pursuant to the full exercise of the underwriters' option to purchase additional common shares. The gross proceeds to Trillium from this offering, before deducting underwriting discounts and commissions and other offering expenses payable by Trillium, were approximately US$55.2 million.
TR.TO: 25.35 (-3.13), TRIL: 20.67 (-2.53)
The Top-Performing Biotech Stock During a Sizzling First Quarter
at The Street - Wed Apr 01, 8:30AM CDT
That was one crazy first quarter for the biotech sector. Here's where biotech stocks stand on April Fool's Day.
CRMD: 8.86 (-0.28), BIIB: 423.57 (+1.46), ESPR: 100.53 (-2.60), FMI: 48.71 (-0.96), ANTH: 4.79 (+0.10), XBI: 232.63 (-0.32), IBB: 363.84 (-0.66), TRIL: 20.67 (-2.53)
Trillium prices equity offering
Seeking Alpha - at Seeking Alpha - Wed Apr 01, 8:06AM CDT
TRIL: 20.67 (-2.53)
Trillium Therapeutics Announces Pricing of Public Offering of Securities
GlobeNewswire - Wed Apr 01, 6:00AM CDT
Trillium Therapeutics Inc. (Nasdaq:TRIL) (TSX:TR) an immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has priced an underwritten public offering of 1,522,395 common shares and 1,077,605 non-voting convertible preferred shares at a price of US$19.50 per share for aggregate gross proceeds of US$50.7 million before deducting underwriting discounts and commissions and other offering expenses.
TR.TO: 25.35 (-3.13), TRIL: 20.67 (-2.53)
Trillium Therapeutics initiates equity offering
Seeking Alpha - at Seeking Alpha - Mon Mar 30, 3:16PM CDT
TRIL: 20.67 (-2.53)
Trillium Therapeutics Announces Proposed Public Offering of Securities
GlobeNewswire - Mon Mar 30, 3:01PM CDT
Trillium Therapeutics Inc. (Nasdaq:TRIL) (TSX:TR) an immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it is offering to sell US$50,000,000 of common shares and preferred shares in an underwritten public offering. The preferred shares are being offered to certain of Trillium's existing shareholders whose purchase of common shares in this offering may result in such shareholder, together with its affiliates and certain related parties, beneficially owning more than 4.99% of Trillium's outstanding common shares following the consummation of this offering. Trillium also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the total number of common shares to be sold in this offering.
TR.TO: 25.35 (-3.13), TRIL: 20.67 (-2.53)
Trillium Announces Appointment of Eric L. Sievers, M.D. as Chief Medical Officer
GlobeNewswire - Fri Mar 27, 6:00AM CDT
Trillium Therapeutics Inc. ("Trillium"
(Nasdaq:TRIL) (TSX:TR), an immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that Eric L. Sievers, M.D., has assumed the position of Chief Medical Officer. In this role, he will lead the company in evaluating and implementing clinical development strategies for advancement and approval of its clinical programs, with initial emphasis on the company's CD47 program. TR.TO: 25.35 (-3.13), TRIL: 20.67 (-2.53)
Trillium Therapeutics to Present at the 5th Annual Cancer Immunotherapy Conference
GlobeNewswire - Wed Mar 25, 1:45PM CDT
Trillium Therapeutics Inc. (Nasdaq:TRIL) (TSX:TR), an immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that Robert Uger, PhD, the Company's Chief Scientific Officer, will be presenting at the 5th Annual "Cancer Immunotherapy: A Long Awaited Reality" Conference at the New York Academy of Medicine in New York City on March 26, 2015. The corporate presentation is scheduled for 10:00 AM Eastern Time and Dr. Uger will be participating on the panel: Checkpoint Modulators - Next Generation.
TR.TO: 25.35 (-3.13), TRIL: 20.67 (-2.53)
Bloom Burton's David Martin Zeroes In On Under-The-Radar Biotech
Life Sciences Report - Seeking Alpha - Fri Feb 13, 9:24AM CST
Biotechnology indices have been on a rapid ascent for three years, and 2015 appears to be off to the races as well. Bloom Burton & Co.'s David Martin has taken his seat in the grandstands, betting on specialty pharma and biotech companies based...
AUPH: 3.85 (+0.05), TRIL: 20.67 (-2.53)
So Far in 2015, This Choppy Market Is for Stock-Picker's Only
at The Street - Wed Jan 28, 12:55PM CST
With no clear direction in the market, picking individual stocks has been key to making money in 2015.
HABT: 33.00 (+0.55), EPRS: 8.74 (-0.25), TRIL: 20.67 (-2.53), FSI: 1.46 (+0.03)
Trillium Therapeutics Starts the New Year on a Surge of 28.5%: Analyst Report Issued by BrokerBank Securities, Inc.
PR Newswire - Fri Jan 09, 6:00AM CST
Trillium Therapeutics Inc. (NASDAQ: TRIL) based in Toronto, Canada has seen a price surge since its recent listing on the US NASDAQ exchange. The immune-oncology company is focusing efforts on the flagship SIRPaFc compound and is expected to submit an IND in mid-2015. Moving to the US market and consolidating the shares proved to be very profitable for the company and helped appreciate the share price nearly 100% on both the TSX and NSADAQ tickers.
TRIL: 20.67 (-2.53)
After CAR-T: Getting Ahead of the Next Hot Trend in Cancer Stocks
at The Street - Tue Jan 06, 7:30AM CST
Here's how investors can help fund the next cure for cancer: anti-CD47 antibody therapies.
BLUE: 136.49 (+1.22), KITE: 57.56 (-1.43), JUNO: 55.72 (-0.68), TRIL: 20.67 (-2.53), CELG: 115.54 (+0.72)
Trillium Therapeutics up premarket
Seeking Alpha - at Seeking Alpha - Wed Dec 31, 8:26AM CST
TRIL: 20.67 (-2.53)
OTC Markets Group Congratulates Trillium Therapeutics on NASDAQ Listing
PR Newswire - Mon Dec 22, 7:00AM CST
OTC Markets Group Inc. (OTCQX: OTCM) congratulates Trillium Therapeutics Inc., an immuno-oncology company developing innovative therapies for the treatment of cancer, on its recent NASDAQ listing. Trillium previously traded on OTCQX®, the best marketplace for established, global and growth companies operated by OTC Markets Group.
TRIL: 20.67 (-2.53)
